Artivion, Inc. (AORT)
NYSE: AORT · Real-Time Price · USD
28.65
-0.01 (-0.03%)
Jun 5, 2025, 10:35 AM - Market open
Artivion Revenue
Artivion had revenue of $98.98M in the quarter ending March 31, 2025, with 1.59% growth. This brings the company's revenue in the last twelve months to $390.08M, up 5.94% year-over-year. In the year 2024, Artivion had annual revenue of $388.54M with 9.75% growth.
Revenue (ttm)
$390.08M
Revenue Growth
+5.94%
P/S Ratio
3.08
Revenue / Employee
$243,803
Employees
1,600
Market Cap
1.35B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 388.54M | 34.53M | 9.75% |
Dec 31, 2023 | 354.00M | 40.22M | 12.82% |
Dec 31, 2022 | 313.79M | 14.95M | 5.00% |
Dec 31, 2021 | 298.84M | 45.61M | 18.01% |
Dec 31, 2020 | 253.23M | -23.00M | -8.32% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AORT News
- 1 day ago - Artivion to Participate in Upcoming Investor Conferences - PRNewsWire
- 7 days ago - Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock - PRNewsWire
- 21 days ago - Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock - PRNewsWire
- 4 weeks ago - Artivion, Inc. (AORT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Artivion Reports First Quarter 2025 Financial Results - PRNewsWire
- 4 weeks ago - Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting - PRNewsWire
- 6 weeks ago - Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results - PRNewsWire
- 3 months ago - Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference - PRNewsWire